Showing 3081-3090 of 3315 results for "".
- Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476963/On the eve of World Sight Day, Orbis International is celebrating achievements of the eye health community over the past two decades, and warns of a projected global tripling in demand for eye care over the next 30 years. 2020 is a critical year for Orbis International and other leaders in
- Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and New IOL Data at AAOhttps://modernod.com/news/alcon-to-highlight-acrysof-iq-panoptix-trifocal-iol-launch-and-groundbreaking-iol-data-at-aao/2476961/Alcon announced its plans to lead a wide range of informational and peer-to-peer educational programs at the American Academy of Ophthalmology (AAO) annual meeting on October 12-15 in San Francisco. The newly launched AcrySof IQ PanOptix Trifocal IOL, along with findings from the AAO IRIS (Intell
- Eyeris Announces Industry-First, Environmentally-Conscious Packaginghttps://modernod.com/news/eyeris-announces-industry-first-environmentally-conscious-packaging/2476959/Nashville-based start-up Eyeris recently announced its daily disposable contact lens that will be launching in January of 2020. Along with the lens, Eyeris created industry-first trial lens packa
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476950/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated in the equity round and provi
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476948/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated significantly in the equity r
- On World Sight Day, Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/on-world-sight-day-orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476936/Today, Orbis International commemorates World Sight Day by celebrating achievements of the eye health community over the past two decades, and warning of a projected global tripling of blindness over the next 30 years. Next year is a critical year for Orbis International and other leaders
- Johnson & Johnson Vision Care Introduces Acuvue RevitaLens Multi-Purpose Disinfecting Solutionhttps://modernod.com/news/johnson-johnson-vision-care-introduces-acuvue-revitalens-multi-purpose-disinfecting-solution/2476925/Johnson & Johnson Vision has unveiled the first extension of the Acuvue brand name beyond contact lenses with the launch of Acuvue RevitaLens Multi-Purpose Disinfecting Solution (MPDS). Acuvue RevitaLens MPDS delivers disinfection and all-day comfort for reusable contact lens wearers. Its dua
- Clinreg Consulting Services Appoints New President and Plans to Expand Consulting Teamhttps://modernod.com/news/clinreg-consulting-services-appoints-new-president-and-plans-to-expand-consulting-team/2476920/Clinreg Consulting Services, a provider of regulatory, clinical, statistical, data management, and quality consulting services, announced the appointment of Lee Kramm, MD, MSE, as President and plans to expand its con
- GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase 3 Trial of GS010 for the Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/GenSight Biologics reported the first set of results from week 96 of the RESCUE phase 3 clinical trial, which evaluated the efficacy and safety of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropat
- Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driverhttps://modernod.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/The world’s aging population—leading to steady growth in cataract surgeries—and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmic surgical product mar